Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »

Libby's H*O*P*E* › Comments

Libby's H*O*P*E*
Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.. ......... - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
The novel 19q12 ISH probe reliably detects both CCNE1 and URI amplification as confirmed by FISH. The combination of 19q12 amplification with Cyclin E1 and URI protein expression may help to select patients more likely to benefit from CDK2 targeted therapies. - Libby's H*O*P*E*
Libby's H*O*P*E*
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer....... - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
In parallel, initial data reported here from an ongoing Phase 2 clinical study of CRLX101 monotherapy shows measurable tumor reductions in 74% of patients and a 16% RECIST response rate to date. Conclusions: Given these preclinical and initial clinical results, further clinical studies are currently evaluating CRLX101 in combination with bevacizumab in ovarian cancer and warrant the evaluation of this therapy combination in other cancer types where HIF-1α is implicated in pathogenesis, as it may potentially be able to improve the efficacy of anti-angiogenic drugs. - Libby's H*O*P*E*
Libby's H*O*P*E*
PharmaMar reports promising Phase IIb overall survival data for use of PM1183 in platinum-resistant ovarian cancer pts. ......- http://www.eurekalert.org/pub_rel...
In this multicenter Phase IIb randomized trial, platinum-resistant ovarian patients treated with PM1183 lived longer, with a median overall survival of 18.1 months, compared to topotecan, which only achieves 8.5 months. PharmaMar will launch a pivotal Phase III trial to confirm the efficacy of PM1183 in a larger population, and that is expected to be the final step before registration of PM1183 for platinum-resistant ovarian cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. ... [Mol Cancer Ther. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
These results support the clinical evaluation of SGN-LIV1A as a novel therapeutic agent for patients with LIV-1 expressing cancer, including breast, prostate, ovarian and uterine cancers, as well as melanoma). - Libby's H*O*P*E*
Libby's H*O*P*E*
Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer.... [J Oncol. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Single institution study found that decreasing stage at detection from Stage IIIC to stage IIIA epithelial ovarian cancer is associated with a 5-year survival advantage of nearly 20% in patients treated by surgical tumor cytoreduction and platinum-based chemotherapy. - Libby's H*O*P*E*
Libby's H*O*P*E*
Colorado cancer experts launch plan with Japan for 1st US carbon-ion radiotherapy center. .... - http://www.eurekalert.org/pub_rel...
Carbon-ion radiotherapy is notable for creating more lethal damage to DNA in tumor cells – making it effective in killing tumors that are resistant to traditional therapies. Studies show that carbon-ion radiation is safe, well-tolerated by patients and works on many types of cancer with few side effects. - Libby's H*O*P*E*
Libby's H*O*P*E*
ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Technology Licensed from Caltech. ....http://investors.imuc.com/release...
The technology utilizes the patient's own hematopoietic stem cells to create antigen-specific killer T-cells to treat cancer. ImmunoCellular pipeline also includes ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. - Libby's H*O*P*E*
Libby's H*O*P*E*
Statement on risk assessment for inherited gynecologic cancer predispositions. ..... [Gynecol Oncol. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Update to 2007 SGO Clinical Practice Statement re same - Libby's H*O*P*E*
Libby's H*O*P*E*
Aduro BioTech (maker of CRS-207) Named One of Fierce 15 Leading Biotech Companies in 2014. - MarketWatch - http://www.marketwatch.com/story...
CRS-207 is one of a family of product candidates based on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenes immunotherapy platform that induce a potent innate and T cell-mediated immune response. CRS-207 has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian and gastric cancers. - Libby's H*O*P*E*
Libby's H*O*P*E*
Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations.... [J BUON. 2014 Apr-Jun] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
The impact of small bowel syndrome (SBS) on overall survival was very important, as the mean overall survival in the SBS group was 28.6 months vs 41 months in other cytoreductive surgery + HIPEC patients (p<0.001). - Libby's H*O*P*E*
Libby's H*O*P*E*
Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform. ......- http://money.cnn.com/news...
In the oncology platform validation studies, 198 single point serum specimens (taken at the time of cancer diagnosis) were analyzed from patients with Glioblastoma, Metastatic Melanoma, Breast cancer, Ovarian cancer, Colorectal cancer and Pancreatic cancer, plus 20 age-matched, female and male non-cancer controls. In the studies, the ESI platform was consistently able to differentiate individuals afflicted with cancer as compared to non-cancer controls. - Libby's H*O*P*E*
Libby's H*O*P*E*
Deciphera Pharmaceuticals announces phase 1 study of altiratinib (DCC-2701; MET/TIE2/VEGFR/TRK kinase inhibitor) in advanced solid tumors. ...... http://clinicaltrials.gov/ct2...
In preclinical cancer models, altiratinib has shown promising activity against multiple tumors, including melanoma, ovarian, glioblastoma, colorectal, gastric and breast cancers. - Libby's H*O*P*E*
Libby's H*O*P*E*
Nanotax phase I clinical trial shows promise for treating advanced abdominal cancers, including ovarian. .. - See more at: http://www.kucancercenter.org/about-u... http://www.kucancercenter.org/about-u...
During the trial, five out of 21 late-stage cancer patients survived more than 400 days after being treated with Nanotax at high concentrations for more than four weeks. - Libby's H*O*P*E*
Libby's H*O*P*E*
Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial..... [Gynecol Oncol. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
These results suggest that CRP, IL-1α, IL-8, and TNF-α are associated with increased risk of subsequently developing ovarian cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
3V Biosciences opens 1st in human phase 1 study of TVB-2640 (FASN inhibitor) in patients with advanced stage malignant solid tumors - Full Text View - ClinicalTrials.gov - http://clinicaltrials.gov/ct2...
A 2012 preclinical study reported that fatty acid synthase (FASN) expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Review at http://www.ncbi.nlm.nih.gov/pubmed... - Libby's H*O*P*E*
Libby's H*O*P*E*
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer - ClinicalTrials.gov - http://clinicaltrials.gov/ct2...
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. - Libby's H*O*P*E*
Libby's H*O*P*E*
2014 ASCO: Almac Validates Novel Test for Ovarian Cancer Patients...... | Business Wire - http://www.businesswire.com/news...
AADx gene expression biomarker identifies a molecular subgroup of ovarian cancer patients that has better survival following standard chemotherapy but may be disadvantaged by bevacizumab. - Libby's H*O*P*E*
Libby's H*O*P*E*
2014 ASCO: Phase 1 testing of VS-6063 (defactinib; targeting cancer stem cells) + paclitaxel (Taxol) shows early signs of clinical activity (64% clinical benefit rate) in ovarian cancer patients......- http://phx.corporate-ir.net/phoenix...
“These data continue to show that the combination of cancer stem cell-targeting agent VS-6063 and paclitaxel is well tolerated, with no unexpected toxicity or worsening of the well understood side effects of paclitaxel, and support the further study of this combination in the clinic,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “In addition to the demonstration of safety, we continue to see interesting signs of early clinical activity where 14 of 22 (64%) patients enrolled in this study achieved a best overall response of at least stable disease including two partial responses and two complete responses to date.” - Libby's H*O*P*E*
Libby's H*O*P*E*
Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype... ... [Adv Anat Pathol. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
In spite of contradictory results, likely reflective of differences in study design, sample size and methodology, a recurring observation is the overrepresentation of "endometriosis-associated tumors," namely, endometrioid and clear cell subtypes, in the group of ovarian tumors with MMR deficiency. - Libby's H*O*P*E*
Libby's H*O*P*E*
Scientists from USC and NYU design a molecule that blocks cancer growth in mice - http://www.eurekalert.org/pub_rel...
Protein–protein interactions are attractive targets for drug design due to their fundamental role in biological function. However, small molecules that selectively target the intended interactions have been difficult to access using traditional drug discovery approaches. We show that compounds that reproduce key functionality at the interface between transcription factor hypoxia-inducible factor 1α (HIF1α) and coactivator p300 (or CREB binding protein, CBP) can inhibit expression of a multitude of genes under hypoxic environments. The designed inhibitors target the chosen protein–protein interaction in a predictable manner and reduce tumor growth in mouse xenograft models. - Libby's H*O*P*E*
Libby's H*O*P*E*
Molecular Genetics of Clear-Cell Renal Cell Carcinoma - http://jco.ascopubs.org/content...
At least one study has found a genomic similiarity (albeit not identifical) between renal (kidney) clear cell cancer and ovarian clear cell cancer. This finding suggests that targeted therapies used to treat RCCC could also be used to treat OCCC. - Libby's H*O*P*E*
Libby's H*O*P*E*
Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling - http://www.pnas.org/content...
Many chemotherapeutics function by inducing cellular apoptosis, or programmed cell death, in tumor cells. Here, using a unique enzymatically driven technology, we find that numerous protein fragments are released into the bloodstream from apoptotic cells within hours after chemotherapy. These circulating signatures of cell death, if confidently assigned to tumor cells, may form the foundation for entirely novel, rapid, and inexpensive biomarkers of chemotherapeutic efficacy. Diagnostic tests to rapidly assess cell death after treatment could serve an important role in management for many cancers. - Libby's H*O*P*E*
Libby's H*O*P*E*
Adoptive T-Cell Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial (Bile Duct) Cancer - http://www.sciencemag.org/content...
Malignant tumors harbor genetic alterations. Recently, adoptive T cell therapies have taken advantage of this: T cells specific for mutations in tumors are infused into patients to generate an antitumor immune response. Although therapeutic benefit has been seen for melanomas, effectiveness against more common epithelial tumors is unclear. Using whole-exome sequencing, Tran et al. (p. 641) identified tumor-infiltrating CD4+ T cells specific for a mutated antigen expressed by a tumor from a patient with metastatic cholangiocarcinoma. Infusion of this patient with an expanded-population, mutation-specific T cell resulted in tumor regression and stabilization of disease. - Libby's H*O*P*E*
Libby's H*O*P*E*
2014 AACR: Immunovaccine to Present Data on Cancer Vaccine Combination Therapies at the 2014 AACR Annual Meeting - MarketWatch - http://www.marketwatch.com/story...
Combining with cyclophosphamide and the checkpoint inhibitor anti-PD-1 enhances the therapeutic potential of vaccine. - Libby's H*O*P*E*
Libby's H*O*P*E*
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. [Mol Clin Oncol. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Therefore, we considered it justified to classify patients with clear cell/mucinous adenocarcinoma who relapsed within 12 months as platinum-resistant and those who relapsed after 12 months as platinum-sensitive. - Libby's H*O*P*E*
Libby's H*O*P*E*
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression... [Int J Gynecol Cancer. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Dasatinib in combination with relapse chemotherapeutic agents seems to interact in a synergistic or additive manner in cells with high SRC pathway activation and protein expression. - Libby's H*O*P*E*
Libby's H*O*P*E*
Epigenetic determinants of ovarian clear cell carcinoma biology.... [Int J Cancer. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Preclinical study results suggest that decitabine may be effective against ovarian clear cell cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.... [Invest New Drugs. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Eight patients achieved stable disease (SD) ≥ 6 months (six platinum failures) and one patient with platinum-resistant ovarian cancer, partial response (PR) (total SD ≥ 6 months/PR = 9, 16.4 %). - Libby's H*O*P*E*
Libby's H*O*P*E*
2013 AACR-NCI-EORTC Mtg: Verastem's Results Support Continued Development of VS-6063 (defactinib)(FAK inhibitor) Across Multiple Tumor Types, including Ovarian .....http://www.businesswire.com/news...
Results from the Phase 1 dose escalation portion of the study were presented. Six patients with advanced or refractory ovarian cancer, all of whom had prior taxane exposure and were platinum resistant, were enrolled. Two patients demonstrated significant decreases, or normalization, of CA-125, a marker that becomes elevated with disease progression in ovarian cancer. One patient in the VS-6063 200mg BID cohort experienced an ongoing complete response as confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) with repeated radiologic scans and a second patient in the VS-6063 400mg BID cohort continues to experience prolonged stabilization of her disease. Patient recruitment remains ongoing in the expansion Phase 1b open-label, multicenter portion of the study, where Verastem expects to enroll a total of approximately 15 patients at three U.S. locations. - Libby's H*O*P*E*
Libby's H*O*P*E*
Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug ME-344 Reveals 35% Disease Control Rate in Refractory Solid Tumors - http://investor.meipharma.com/2013-10...
As reported in the abstract of the presentation, eight of the 23 patients evaluable for efficacy (35%) achieved disease control, including one confirmed partial response (PR) in a patient with refractory small cell lung cancer (duration 52+ weeks) and seven patients with prolonged stable disease (SD) ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg. Based on these findings, MEI Pharma is actively preparing for a phase Ib clinical trial of ME-344 in combination with Hycamtin (topotecan) in small cell lung cancer and ovarian cancer, which it expects to initiate during the second quarter of 2014.” - Libby's H*O*P*E*
Other ways to read this feed:Feed readerFacebook